Jefferies Financial Group lowered shares of Takeda Pharmaceutical (NYSE:TAK) from a buy rating to a hold rating in a research report report published on Monday, The Fly reports.

Separately, Zacks Investment Research lowered shares of Takeda Pharmaceutical from a buy rating to a hold rating in a research note on Friday, February 19th.

TAK stock opened at $17.34 on Monday. The stock’s 50 day simple moving average is $18.24 and its 200 day simple moving average is $17.82. The company has a market cap of $54.67 billion, a P/E ratio of 57.80 and a beta of 1.01. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.08 and a current ratio of 1.51. Takeda Pharmaceutical has a fifty-two week low of $15.30 and a fifty-two week high of $20.00.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, February 4th. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 13.46% and a net margin of 3.04%. The firm had revenue of $8.01 billion during the quarter. Equities analysts predict that Takeda Pharmaceutical will post 2.02 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. Lindbrook Capital LLC boosted its position in shares of Takeda Pharmaceutical by 10.0% during the fourth quarter. Lindbrook Capital LLC now owns 6,430 shares of the company’s stock valued at $117,000 after buying an additional 582 shares during the last quarter. Cerity Partners LLC lifted its stake in Takeda Pharmaceutical by 2.6% during the 4th quarter. Cerity Partners LLC now owns 28,679 shares of the company’s stock valued at $522,000 after acquiring an additional 725 shares in the last quarter. JFS Wealth Advisors LLC boosted its holdings in Takeda Pharmaceutical by 10.7% during the 4th quarter. JFS Wealth Advisors LLC now owns 8,439 shares of the company’s stock worth $154,000 after acquiring an additional 818 shares during the last quarter. ETF Managers Group LLC grew its stake in shares of Takeda Pharmaceutical by 5.6% in the 4th quarter. ETF Managers Group LLC now owns 20,368 shares of the company’s stock worth $370,000 after acquiring an additional 1,071 shares in the last quarter. Finally, Avalon Investment & Advisory raised its holdings in shares of Takeda Pharmaceutical by 0.8% in the fourth quarter. Avalon Investment & Advisory now owns 149,861 shares of the company’s stock valued at $2,727,000 after purchasing an additional 1,254 shares during the last quarter. 3.41% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines.

Recommended Story: How does the Beige Book influence monetary policy?

The Fly

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.